329 related articles for article (PubMed ID: 35563051)
61. Chronic lymphocytic leukaemia.
Scarfò L; Ferreri AJ; Ghia P
Crit Rev Oncol Hematol; 2016 Aug; 104():169-82. PubMed ID: 27370174
[TBL] [Abstract][Full Text] [Related]
62. Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives.
Bagacean C; Tomuleasa C; Tempescul A; Grewal R; Brooks WH; Berthou C; Renaudineau Y
Crit Rev Clin Lab Sci; 2019 Aug; 56(5):321-332. PubMed ID: 30935269
[TBL] [Abstract][Full Text] [Related]
63. [Expression of microRNA-223 in lymphocytic leukemia cells and its action mechanism].
Nan Z; Liang Y; Fu R; Liu H; Ruan EB; Wang XM; Wang GJ; Qu W; Liu H; Wu YH; Song J; Xing LM; Guan J; Li LJ; Wang HQ; Shao ZH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):556-61. PubMed ID: 23815897
[TBL] [Abstract][Full Text] [Related]
64. MicroRNA expression profiles discriminate childhood T- from B-acute lymphoblastic leukemia.
Almeida RS; Costa E Silva M; Coutinho LL; Garcia Gomes R; Pedrosa F; Massaro JD; Donadi EA; Lucena-Silva N
Hematol Oncol; 2019 Feb; 37(1):103-112. PubMed ID: 30393877
[TBL] [Abstract][Full Text] [Related]
65. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221.
Kotani A; Ha D; Hsieh J; Rao PK; Schotte D; den Boer ML; Armstrong SA; Lodish HF
Blood; 2009 Nov; 114(19):4169-78. PubMed ID: 19749093
[TBL] [Abstract][Full Text] [Related]
66. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Hagemeister F
Drugs; 2010 Feb; 70(3):261-72. PubMed ID: 20166765
[TBL] [Abstract][Full Text] [Related]
67. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure.
Beesley AH; Cummings AJ; Freitas JR; Hoffmann K; Firth MJ; Ford J; de Klerk NH; Kees UR
Br J Haematol; 2005 Nov; 131(4):447-56. PubMed ID: 16281934
[TBL] [Abstract][Full Text] [Related]
68. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
69. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
Zhu DX; Zhu W; Fang C; Fan L; Zou ZJ; Wang YH; Liu P; Hong M; Miao KR; Liu P; Xu W; Li JY
Carcinogenesis; 2012 Jul; 33(7):1294-301. PubMed ID: 22610076
[TBL] [Abstract][Full Text] [Related]
70. MicroRNAs and cancer resistance: A new molecular plot.
Fanini F; Fabbri M
Clin Pharmacol Ther; 2016 May; 99(5):485-93. PubMed ID: 26875151
[TBL] [Abstract][Full Text] [Related]
71. Simultaneous changes in expression levels of BAALC and miR-326: a novel prognostic biomarker for childhood ALL.
Ghodousi ES; Aberuyi N; Rahgozar S
Jpn J Clin Oncol; 2020 Jun; 50(6):671-678. PubMed ID: 32129446
[TBL] [Abstract][Full Text] [Related]
72. Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.
Zheng G; Chattopadhyay S; Sud A; Sundquist K; Sundquist J; Försti A; Houlston R; Hemminki A; Hemminki K
Br J Haematol; 2019 Apr; 185(2):232-239. PubMed ID: 30706458
[TBL] [Abstract][Full Text] [Related]
73. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
[TBL] [Abstract][Full Text] [Related]
74. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
[TBL] [Abstract][Full Text] [Related]
75. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
[TBL] [Abstract][Full Text] [Related]
76. Targeting BTK through microRNA in chronic lymphocytic leukemia.
Bottoni A; Rizzotto L; Lai TH; Liu C; Smith LL; Mantel R; Reiff S; El-Gamal D; Larkin K; Johnson AJ; Lapalombella R; Lehman A; Plunkett W; Byrd JC; Blachly JS; Woyach JA; Sampath D
Blood; 2016 Dec; 128(26):3101-3112. PubMed ID: 27756747
[TBL] [Abstract][Full Text] [Related]
77. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
[TBL] [Abstract][Full Text] [Related]
78. Role of microRNAs in Chronic Lymphocytic Leukemia Pathogenesis.
Javandoost E; Firoozi-Majd E; Rostamian H; Khakpoor-Koosheh M; Mirzaei HR
Curr Med Chem; 2020; 27(2):282-297. PubMed ID: 31544709
[TBL] [Abstract][Full Text] [Related]
79. microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters.
Negrini M; Cutrona G; Bassi C; Fabris S; Zagatti B; Colombo M; Ferracin M; D'Abundo L; Saccenti E; Matis S; Lionetti M; Agnelli L; Gentile M; Recchia AG; Bossio S; Reverberi D; Rigolin G; Calin GA; Sabbioni S; Russo G; Tassone P; Morabito F; Ferrarini M; Neri A
Clin Cancer Res; 2014 Aug; 20(15):4141-53. PubMed ID: 24916701
[TBL] [Abstract][Full Text] [Related]
80. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
